This event begins in
  • Days
  • Hours
  • Minutes
A zoom link will be available on the day of this event.
  • April 16, 2026
  • 8:00 PM EST

National Cornerstone Corner, 8:00 PM

National Cornerstone Corner, 8:00 PM

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Program Chairs

M. Yair Levy, MD

Sponsors

 

This program is not CME accredited.
In addition to the Program's educational offerings, a separate portion involves market research sessions for which a fair market value honorarium will be offered to eligible registrants who choose to participate. Additional details are listed on the registration page and dependent on registrant's designation.